Skip to content
TrialScanner

NCT06332092

FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma

Phase 2Active, not recruitingFLGTLead

Registry record

Lead sponsor
Fulgent Pharma LLC.
Conditions
Head and Neck Squamous Cell Carcinoma
Primary completion
Dec 31, 2025Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT06332092 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT06332092: FID-007 and Cetuximab in... | TrialScanner